Table 1.

Summary of incidence of cough with perindopril in clinical studies.

Name of study/Author	Type of study	Perindopril	Cough Incidence (%)
PIANIST23	Observational	Perindopril, 10 mg	0.8
PAINT24	Observational	Perindopril, 5 and 10 mg	<0.1
PETRA25	Observational	Perindopril, 5 mg and 10 mg	0.04
GREEK cohort60	Observational	Perindopril, 5 mg and 10 mg	0.001
PROOF22	Observational	Perindopril, 5 mg and 10 mg
Nedogoda SV et al.61	Randomized	Perindopril 5 mg	No incidence was reported (0)
Mourad JJ et al62	Randomized	Perindopril, 5 mg and 10 mg	1.1
PROTECT I63	Observational	Perindopril 4 mg, 8 mg	4.3
Sandeep Bansal et al.21		Perindopril, N = 1250	Monotherapy: 3.6
			Combination:1.8 and 4.3
STRONG17		Perindopril, N = 427	3.2
MV Padma et al.18		Perindopril, N = 298	4

PIANIST, Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients; PAINT, Perindopril-Amlodipine plus Indapamide combination for controlled hypertension Non-intervention Trial; PETRA, The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine; PROOF, Combined Therapy of Arterial Hypertension With a Triple Fixed-Dose Combination of Amlodipine/Indapamide/ Perindopril Arginine in Real Clinical Practice; PROTECT, Effectiveness of PeRindOpril in the management of hyperTension: idEntification of patient and physiCian determinants of response to Treatment; STRONG, SafeTy & efficacy analysis of coveRsyl amlodipine in uncOntrolled and Newly diaGnosed hypertension.